Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    10817555 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Daclizumab to Treat Wegener's Granulomatosis
Condition: Wegener's Granulomatosis
Intervention: Drug: Daclizumab
2 Completed An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
Condition: Wegener's Granulomatosis
Intervention: Drug: Rituximab

Indicates status has not been verified in more than two years